Roquefort Therapeutics (LON:ROQ) Trading Down 9.7% – Here’s Why

Shares of Roquefort Therapeutics plc (LON:ROQ) fell 9.7% during trading on Tuesday . The company traded as low as GBX 1.39 ($0.02) and last traded at GBX 1.40 ($0.02). 510,395 shares were traded during mid-day trading, a decline of 77% from the average session volume of 2,232,834 shares. The stock had previously closed at GBX 1.55 ($0.02).

Roquefort Therapeutics Price Performance

The stock has a market cap of £1.76 million, a P/E ratio of -1.14 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The business’s fifty day moving average price is GBX 1.65 and its 200 day moving average price is GBX 2.41.

Roquefort Therapeutics (LON:ROQ) last issued its quarterly earnings data on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.